Cancer Channel
Related Channels


Administered intravenously (by IV), eribulin is a medicine licensed to treat late-stage breast cancer that has not responded adequately to other cancer treatments. This prescription chemotherapy drug prevents cancer cells from dividing, which eventually causes the cancer cells to die. As with most chemotherapy medications, serious reactions are common with eribulin and can include fatigue, nerve problems, and low white blood cells.

What Is Eribulin?

Eribulin mesylate (Halaven™) is a chemotherapy medication approved for the treatment of breast cancer. It is approved to treat late-stage cancer that has not responded to certain other chemotherapy regimens.
(Click What Is Eribulin Used For? for more information, including possible off-label uses.)

Are There Side Effects?

Just like any medicine, eribulin can cause side effects. However, not everyone who takes the medication will have problems. In fact, some people tolerate it quite well, although most people will develop side effects.
If side effects do occur, in many cases, they are minor and either require no treatment or are treated easily by you or your healthcare provider. However, as with most chemotherapy medications, serious side effects are quite common.
Common side effects of eribulin include but are not limited to:
  • Neutropenia (low levels of a certain type of white blood cell called neutrophils)
  • Fatigue or weakness
  • Hair loss
  • Nerve problems, such as nerve pain or unusual sensations.
(Click Side Effects of Eribulin to learn more, including potentially serious side effects that you should report immediately to your healthcare provider.)
5 Easy Tips to Manage Visitors During Cancer Treatment

Eribulin Medication Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2020 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.